The Long Run with Luke Timmerman

David Schenkein, a general partner at GV and a seasoned hematologist, shares insights from his journey in biotech. He discusses the importance of company culture and how his diverse background shaped his investment philosophy. Schenkein emphasizes embracing failure as a vital part of innovation and reveals the interplay between AI and drug discovery. He reflects on his transition from CEO to venture capitalist, underlining the need for diverse strategies in investing. His vision focuses on patient outcomes and the transformative potential of biotech advancements.

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Chris Garcia, a biochemistry professor at Stanford and biotech entrepreneur, dives into the fascinating world of protein engineering for cancer and autoimmune treatments. He shares his transformative journey from aspiring tennis player to leading immunology research. Topics include the ingenious application of AI in protein design, innovative strategies for enhancing clinical trials, and the significance of T-cell interactions in cancer therapies. Personal anecdotes of endurance running cleverly illustrate how these experiences spark creative breakthroughs in science.

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.

Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.

Sarah Boyce, CEO of Avidity Biosciences, shares her inspiring journey from Liverpool to leading a company focusing on RNA medicines for rare muscle diseases. She discusses the innovative therapies being developed for conditions like myotonic dystrophy and Duchenne muscular dystrophy. The conversation dives into the challenges of transitioning to a CEO role and the significance of emotional intelligence in leadership. Boyce also highlights advancements in RNA therapeutics, including promising drug trials and the importance of community engagement in biotechnology.

Sean McClain, CEO of Absci, discusses using AI to speed up biologic drug discovery. Topics include the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025, integrating AI into drug discovery, the creative aspects of biologic drug discovery, engineering E. coli for biologic therapies, evolving business models in biologic drug discovery, unexpected discoveries in drug compound affinity, and revolutionizing drug discovery with AI-generated biologics.

Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.